OGEA-102 practice question 8 of 10

Please read this scenario prior to answering the question You are serving as the Lead Architect for an Enterprise Architecture team within a leading…

Full set: 34 questions

Please read this scenario prior to answering the question You are serving as the Lead Architect for an Enterprise Architecture team within a leading multinational biotechnology company. The company works in three major industries, including healthcare, crop production, and agriculture. Your team works within the healthcare division. The healthcare division is developing a new vaccine, and has to demonstrate its effectiveness and safety in a set of clinical trials that satisfy the regulatory requirements of the relevant health authorities. The clinical trials are undertaken by its research laboratories at multiple facilities worldwide. In addition to internal research and development activities, the healthcare division is also involved in publicly funded collaborative research projects with industrial and academic partners. The Enterprise Architecture team has been engaged in an architecture project to develop a secure system that will allow the healthcare researchers to share information more easily about their clinical trials, and work more collaboratively across the organization and also with its partners. This system will also connect with external partners. The Enterprise Architecture team uses the TOGAF ADM with extensions required to support healthcare manufacturing practices and laboratory practices. Due to the highly sensitive nature ofthe information that is managed, special care has been taken to ensure that each architecture domain considers the security and privacy issues that are relevant. The Vice President for Worldwide Clinical Research is the sponsor of the Enterprise Architecture activity. She has stated that disruptions must be minimized for the clinical trials, and that the rollout must be undertaken incrementally. Refer to the scenario You have been asked to recommend the approach to identify the work packages for an incremental rollout meeting the requirements. Based on the TOGAF standard which of the following is the best answer?

Answer options
A:

A. You recommend that the Solution Building Blocks from a Consolidated Gaps, Solutions and Dependencies Matrix be grouped into a set of work packages. Using the matrix as a planning tool, regroup the work packages to account for dependencies. Sequence the work packages into the Capability Increments needed to achieve the Target Architecture, so that the implementation team can schedule the rollout one region at a time to minimize disruption. Document the work packages for the Enterprise Architecture using a Transition Architecture State Evolution Table.
B:

B. You recommend that a Consolidated Gaps. Solutions and Dependencies Matrix is used as a planning tool for creating work packages. For each gap classify whether the solution is either a new development, purchased solution, or based on an existing product. Group the similar solutions together to define the work packages. Regroup the work packages into a set of Capability Increments to transition to the Target Architecture considering the schedule for clinical trials, and document in an Architecture Definition Increments Table.

 Correct answer
C:

C. You recommend that an Implementation Factor Catalog is drawn up to indicate actions and constraints. A Consolidated Gaps. Solutions and Dependencies Matrix should also be created. For each gap. identify a proposed solution and classify it as new development, purchased solution, or based on an existing product. Group similar activities together to form work packages. Identify dependencies between work packages factoring in the clinical trial schedules. Regroup the work packages into a set of Capability Increments scheduled into a series of Transition Architectures.
D:

D. You recommend that the set of required Solution Building Blocks be determined by identifying those which need to be developed and which need to be procured. Eliminate any duplicates. Group the remaining Solution Building Blocks together to create the work packages using a CRUD (create, read, update, delete) matrix. Rank the work packages and select the most cost-effective options for inclusion in a series of Transition Architectures. Schedule the roll out of the work packages to be sequential across the geographic regions.
Correct Answer:
B. B. You recommend that a Consolidated Gaps. Solutions and Dependencies Matrix is used as a planning tool for creating work packages. For each gap classify whether the solution is either a new development, purchased solution, or based on an existing product. Group the similar solutions together to define the work packages. Regroup the work packages into a set of Capability Increments to transition to the Target Architecture considering the schedule for clinical trials, and document in an Architecture Definition Increments Table.
Explanation

This approach aligns directly with the TOGAF ADM, particularly Phase E (Opportunities and Solutions) and Phase F (Migration Planning). It correctly uses the Consolidated Gaps, Solutions, and Dependencies Matrix as a primary planning tool. The classification of solutions (new development, purchased, or existing) is a key step in Phase E for determining the nature of the work packages. Crucially, it addresses the sponsor's primary constraint by regrouping work packages into Capability Increments while "considering the schedule for clinical trials" to minimize disruption. Finally, it correctly identifies the "Architecture Definition Increments Table" as the specific TOGAF artifact used to document the grouping of projects/work packages into increments.

Why Incorrect

A: This option incorrectly prescribes a specific rollout strategy (regional) not mandated by the scenario and uses a less precise artifact for documenting the increments. C: While containing correct elements, its flow is less direct, and it does not explicitly link the creation of Capability Increments to the critical business constraint (clinical trial schedules). D: This option is fundamentally incorrect as it proposes using a CRUD matrix, which is a data architecture tool, for grouping Solution Building Blocks into work packages for migration planning.

References

1. TOGAF® Standard, Version 9.2, Chapter 11 (Phase E: Opportunities and Solutions): Section 11.4.3, "Create the Architecture Roadmap", describes the creation of a Consolidated Gaps, Solutions, and Dependencies Matrix and the identification of work packages that group related activities. It also covers the classification of solutions as new, purchased, or based on existing products.

2. TOGAF® Standard, Version 9.2, Chapter 12 (Phase F: Migration Planning): Section 12.5, Step 4, "Group the projects into Transition Architectures", details the process of creating Capability Increments. It emphasizes that the grouping should be based on business value, dependencies, and reduction of risk, which aligns with considering the clinical trial schedules to minimize disruption.

3. TOGAF® Standard, Version 9.2, Section 31.6.2 (Artifacts in the Architecture Repository): This section defines the "Architecture Definition Increments Table" as the artifact that lists projects grouped into increments. It also defines the "Consolidated Gaps, Solutions, and Dependencies Matrix" as a key output of Phase E.

4. TOGAF® Standard, Version 9.2, Section 9.6.3 (Phase C: Information Systems Architectures — Data Architecture): This section describes the Data/Application matrix (often a CRUD matrix), confirming its purpose is to map data entities to applications, not for creating implementation work packages.

Keep practicing

Take the free OGEA-102 practice test

Ten exam-style questions with answers and explanations, plus the exam facts and study guides.

Start the free practice test

More questions

Other OGEA-102 practice questions

Scroll to Top